{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:09:08Z","timestamp":1791216548892,"version":"4.1.0"},"reference-count":132,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Purpose of Review: Advances in pharmacogenomics have paved the way for personalized medicine. Cardiovascular diseases still represent the leading cause of mortality in the world. The aim of this review is to summarize the background, rationale, and evidence of pharmacogenomics in cardiovascular medicine, in particular, the use of antiplatelet drugs, anticoagulants, and drugs used for the treatment of dyslipidemia. Recent findings: Randomized clinical trials have supported the role of a genotype-guided approach for antiplatelet therapy in patients with coronary heart disease undergoing percutaneous coronary interventions. Numerous studies demonstrate how the risk of ineffectiveness of new oral anticoagulants and vitamin K anticoagulants is linked to various genetic polymorphisms. Furthermore, there is growing evidence to support the association of some genetic variants and poor adherence to statin therapy, for example, due to the appearance of muscular symptoms. There is evidence for resistance to some drugs for the treatment of dyslipidemia, such as anti-PCSK9. Summary: Pharmacogenomics has the potential to improve patient care by providing the right drug to the right patient and could guide the identification of new drug therapies for cardiovascular disease. This is very important in cardiovascular diseases, which have high morbidity and mortality. The improvement in therapy could be reflected in the reduction of healthcare costs and patient mortality.<\/jats:p>","DOI":"10.3390\/genes14112057","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T08:08:58Z","timestamp":1699517338000},"page":"2057","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7060-6938","authenticated-orcid":false,"given":"Alfredo","family":"Mauriello","sequence":"first","affiliation":[{"name":"Cardiology Unit, Department of Medical Translational Science, University of Campania \u201cLuigi Campania\u201d\u2014Monaldi Hospital, 80126 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Ascrizzi","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medical Translational Science, University of Campania \u201cLuigi Campania\u201d\u2014Monaldi Hospital, 80126 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Molinari","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medical Translational Science, University of Campania \u201cLuigi Campania\u201d\u2014Monaldi Hospital, 80126 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5669-574X","authenticated-orcid":false,"given":"Luigi","family":"Falco","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medical Translational Science, University of Campania \u201cLuigi Campania\u201d\u2014Monaldi Hospital, 80126 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7761-7533","authenticated-orcid":false,"given":"Alfredo","family":"Caturano","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Campania Luigi Vanvitelli, 80100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9698-9145","authenticated-orcid":false,"given":"Antonello","family":"D\u2019Andrea","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medical Translational Science, University of Campania \u201cLuigi Campania\u201d\u2014Monaldi Hospital, 80126 Naples, Italy"},{"name":"Unit of Cardiology, \u201cUmberto I\u201d Hospital, Nocera Inferiore, 84014 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9227-0360","authenticated-orcid":false,"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medical Translational Science, University of Campania \u201cLuigi Campania\u201d\u2014Monaldi Hospital, 80126 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"ref_1","first-page":"879","article-title":"Drug-Drug-Gene Interactions in Cardiovascular Medicine","volume":"15","author":"Asiimwe","year":"2022","journal-title":"Pharm. Pers. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s40265-013-0126-z","article-title":"Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties","volume":"73","author":"Ferri","year":"2013","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Falco, L., Tessitore, V., Ciccarelli, G., Malvezzi, M., D\u2019Andrea, A., Imbalzano, E., Golino, P., and Russo, V. (2023). Antioxidant Properties of Oral Antithrombotic Therapies in Atherosclerotic Disease and Atrial Fibrillation. Antioxidants, 12.","DOI":"10.3390\/antiox12061185"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","article-title":"Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients Treated with Percutaneous Coronary Intervention","volume":"57","author":"Campo","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of Cytochrome P450 2C19 Genotype with the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated with Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention with Drug-Eluting or Bare-Metal Stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","article-title":"Point-of-Care Genetic Testing for Personalisation of Antiplatelet Treatment (RAPID GENE): A Prospective, Randomised, Proof-of-Concept Trial","volume":"379","author":"Roberts","year":"2012","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2011.1703","article-title":"Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients with Stable Cardiovascular Disease","volume":"306","author":"Mega","year":"2011","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated with Clopidogrel Predominantly for PCI: A Meta-Analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1001\/jama.2011.1880","article-title":"CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events: A Systematic Review and Meta-Analysis","volume":"306","author":"Holmes","year":"2011","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 Single Nucleotide Polymorphisms on Outcomes of Treatment with Ticagrelor versus Clopidogrel for Acute Coronary Syndromes: A Genetic Substudy of the PLATO Trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2018.02.029","article-title":"Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients with Acute Coronary Syndromes","volume":"71","author":"Notarangelo","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.2217\/pgs.09.143","article-title":"Clopidogrel Pharmacogenomics and Risk of Inadequate Platelet Inhibition: US FDA Recommendations","volume":"10","author":"Ellis","year":"2009","journal-title":"Pharmacogenomics"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients with Coronary Stent Placement","volume":"121","author":"Sibbing","year":"2010","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the Management of Acute Coronary Syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Rossello","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short Dual Antiplatelet Therapy Followed by P2Y12 Inhibitor Monotherapy vs. Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Second-Generation Drug-Eluting Stents: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/phar.2758","article-title":"Pharmacogenetics of P2Y 12 Receptor Inhibitors","volume":"43","author":"Thomas","year":"2023","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jama.2016.8662","article-title":"Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients with Minor Stroke or Transient Ischemic Attack","volume":"316","author":"Wang","year":"2016","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.116.024913","article-title":"Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis","volume":"135","author":"Pan","year":"2017","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00228-022-03346-7","article-title":"Clinical Non-Effectiveness of Clopidogrel Use for Peripheral Artery Disease in Patients with CYP2C19 Polymorphisms: A Systematic Review","volume":"78","author":"Huang","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2022.08.001","article-title":"CYP2C19 Genotype-Guided Antithrombotic Treatment versus Conventional Clopidogrel Therapy in Peripheral Arterial Disease: Study Design of a Randomized Controlled Trial (GENPAD)","volume":"254","author":"Kranendonk","year":"2022","journal-title":"Am. Heart J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/eurheartj\/ehv116","article-title":"Effect of Genetic Variations on Ticagrelor Plasma Levels and Clinical Outcomes","volume":"36","author":"Varenhorst","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic Variants in ABCB1 and CYP2C19 and Cardiovascular Outcomes after Treatment with Clopidogrel and Prasugrel in the TRITON-TIMI 38 Trial: A Pharmacogenetic Analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11239-015-1264-9","article-title":"PON1 Q192R Genetic Variant and Response to Clopidogrel and Prasugrel: Pharmacokinetics, Pharmacodynamics, and a Meta-Analysis of Clinical Outcomes","volume":"41","author":"Mega","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_31","first-page":"1575","article-title":"Comparison Between Clopidogrel and Prasugrel Associated with CYP2C19 Genotypes in Patients Receiving Percutaneous Coronary Intervention in a Japanese Population","volume":"84","author":"Sawayama","year":"2020","journal-title":"Circ. J. Off. J. Jpn. Circ. Soc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The Mechanism of Action of Aspirin","volume":"110","author":"Vane","year":"2003","journal-title":"Thromb. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/pgs-2019-0133","article-title":"The Emergent Phenomenon of Aspirin Resistance: Insights from Genetic Association Studies","volume":"21","author":"Ferreira","year":"2020","journal-title":"Pharmacogenomics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1742-1241.2007.01344.x","article-title":"The Genetics of Aspirin Resistance: The Genetics of Aspirin Resistance","volume":"61","author":"Goodman","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pharmthera.2013.08.005","article-title":"Mechanisms of Aspirin Resistance","volume":"141","author":"Floyd","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/clc.22031","article-title":"Aspirin Resistance: Current Status and Role of Tailored Therapy","volume":"35","author":"Grinstein","year":"2012","journal-title":"Clin. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/eurheartj\/ehn562","article-title":"Interindividual Variability in the Response to Oral Antiplatelet Drugs: A Position Paper of the Working Group on Antiplatelet Drugs Resistance Appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, Endorsed by the Working Group on Thrombosis of the European Society of Cardiology","volume":"30","author":"Kuliczkowski","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.2174\/138161212803251907","article-title":"Pharmacogenetics of the Antiplatelet Effect of Aspirin","volume":"18","author":"Wurtz","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5551\/jat.14092","article-title":"Platelet Response to Aspirin in Chinese Stroke Patients Is Independent of Genetic Polymorphisms of COX-1 C50T and COX-2 G765C","volume":"20","author":"Yi","year":"2013","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1160\/TH05-07-0516","article-title":"Polymorphisms of COX-1 and GP VI Associate with the Antiplatelet Effect of Aspirin in Coronary Artery Disease Patients","volume":"95","author":"Mikkelsson","year":"2006","journal-title":"Thromb. Haemost."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1161\/01.ATV.0000030340.80207.C5","article-title":"Common Promoter Variant in Cyclooxygenase-2 Represses Gene Expression: Evidence of Role in Acute-Phase Inflammatory Response","volume":"22","author":"Papafili","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11239-012-0777-8","article-title":"Association of COX-2 Rs20417 with Aspirin Resistance","volume":"35","author":"Sharma","year":"2013","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e22331","DOI":"10.1002\/jcla.22331","article-title":"Association of GPI a and COX-2 Gene Polymorphism with Aspirin Resistance","volume":"32","author":"Wang","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2141.2000.02267.x","article-title":"Relationship between Bleeding Time, Aspirin and the PlA1\/A2 Polymorphism of Platelet Glycoprotein IIIa: Short Report","volume":"110","author":"Szczeklik","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2125.2008.03183.x","article-title":"Pharmacogenetics of Aspirin Resistance: A Comprehensive Systematic Review","volume":"66","author":"Goodman","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/j.thromres.2010.01.011","article-title":"The GPIIIa PlA Polymorphism and the Platelet Hyperactivity in Tunisian Patients with Stable Coronary Artery Disease Treated with Aspirin","volume":"125","author":"Abderrazek","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/cpt.1959","article-title":"Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population","volume":"108","author":"Lewis","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1161\/ATVBAHA.108.168971","article-title":"A Novel Variant in the Platelet Endothelial Aggregation Receptor-1 Gene Is Associated with Increased Platelet Aggregability","volume":"28","author":"Becker","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"664012","DOI":"10.3389\/fcvm.2021.664012","article-title":"Platelet Endothelial Aggregation Receptor 1 Polymorphism is Associated with Functional Outcome in Small-Artery Occlusion Stroke Patients Treated with Aspirin","volume":"8","author":"Li","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev-pharmtox-051921-092701","article-title":"Pharmacogenetics of Antiplatelet Therapy","volume":"63","author":"Castrichini","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/14796678.1.2.191","article-title":"HMG-CoA Reductase Inhibitor Pharmacogenomics: Overview and Implications for Practice","volume":"1","author":"Zineh","year":"2005","journal-title":"Future Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.phrs.2013.12.002","article-title":"The Pharmacogenomics of Statins","volume":"88","author":"Gelissen","year":"2014","journal-title":"Pharmacol. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/CIRCULATIONAHA.108.773267","article-title":"Alternative Splicing of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Is Associated with Plasma Low-Density Lipoprotein Cholesterol Response to Simvastatin","volume":"118","author":"Medina","year":"2008","journal-title":"Circulation"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacc.2007.05.057","article-title":"Association of the Trp719Arg Polymorphism in Kinesin-Like Protein 6 with Myocardial Infarction and Coronary Heart Disease in 2 Prospective Trials","volume":"51","author":"Iakoubova","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jacc.2007.10.017","article-title":"Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary Syndromes","volume":"51","author":"Iakoubova","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.atherosclerosis.2011.07.126","article-title":"Lack of Association between the Trp719Arg Polymorphism in Kinesin-like Protein-6 and Cardiovascular Risk and Efficacy of Atorvastatin among Subjects with Diabetes on Dialysis: The 4D Study","volume":"219","author":"Hoffmann","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2010.06.022","article-title":"Lack of Association Between the Trp719Arg Polymorphism in Kinesin-Like Protein-6 and Coronary Artery Disease in 19 Case-Control Studies","volume":"56","author":"Assimes","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_58","first-page":"1","article-title":"The Influence of SLCO1B1 (OATP1B1) Gene Polymorphisms on Response to Statin Therapy","volume":"10","author":"Romaine","year":"2010","journal-title":"Pharm. J."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"(2008). SLCO1B1 Variants and Statin-Induced Myopathy\u2014A Genomewide Study. N. Engl. J. Med., 359, 789\u2013799.","DOI":"10.1056\/NEJMoa0801936"},{"key":"ref_60","first-page":"352","article-title":"An Association Study of 43 SNPs in 16 Candidate Genes with Atorvastatin Response","volume":"5","author":"Thompson","year":"2005","journal-title":"Pharm. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2009.11.033","article-title":"The Genetics of Statin-Induced Myopathy","volume":"210","author":"Ghatak","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11584380-000000000-00000","article-title":"Clinical Implications of Pharmacogenetic Variation on the Effects of Statins","volume":"34","author":"Maggo","year":"2011","journal-title":"Drug Saf."},{"key":"ref_63","first-page":"274","article-title":"Intronic Polymorphism in CYP3A4 Affects Hepatic Expression and Response to Statin Drugs","volume":"11","author":"Wang","year":"2011","journal-title":"Pharm. J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/clpt.2014.55","article-title":"Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population-Modeling Approach","volume":"96","author":"Tsamandouras","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/0091270006295063","article-title":"Effect of Polymorphic CYP3A5 Genotype on the Single-Dose Simvastatin Pharmacokinetics in Healthy Subjects","volume":"47","author":"Kim","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/FPC.0000000000000079","article-title":"CYP3A4*22 and CYP3A5*3 Are Associated with Increased Levels of Plasma Simvastatin Concentrations in the Cholesterol and Pharmacogenetics Study Cohort","volume":"24","author":"Kitzmiller","year":"2014","journal-title":"Pharmacogenet. Genom."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0009-9236(03)00121-8","article-title":"Influence of CYP2C9 Polymorphisms on the Pharmacokinetics and Cholesterol-Lowering Activity of (\u2212)-3s,5r-Fluvastatin and (+)-3r,5s-Fluvastatin in Healthy Volunteers","volume":"74","author":"Kirchheiner","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"CR512","DOI":"10.12659\/MSM.883272","article-title":"Lipid-Lowering Effect of Fluvastatin in Relation to Cytochrome P450 2C9 Variant Alleles Frequently Distributed in the Czech Population","volume":"18","author":"Buzkova","year":"2012","journal-title":"Med. Sci. Monit."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.0500269102","article-title":"The Target of Ezetimibe Is Niemann-Pick C1-Like 1 (NPC1L1)","volume":"102","author":"Lisnock","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2165\/00003495-200262160-00002","article-title":"Cholesterol Absorption Inhibitors for the Treatment of Hypercholesterolaemia","volume":"62","author":"Sudhop","year":"2002","journal-title":"Drugs"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/FPC.0b013e3282fe9a2c","article-title":"Disposition of Ezetimibe Is Influenced by Polymorphisms of the Hepatic Uptake Carrier OATP1B1","volume":"18","author":"Oswald","year":"2008","journal-title":"Pharmacogenet. Genom."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MOL.0b013e3280555083","article-title":"Pharmacogenetics and Pharmacogenomics of Cholesterol-Lowering Therapy","volume":"18","author":"Schmitz","year":"2007","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.clpt.2005.11.004","article-title":"Intestinal Expression of P-Glycoprotein (ABCB1), Multidrug Resistance Associated Protein 2 (ABCC2), and Uridine Diphosphate\u2013Glucuronosyltransferase 1A1 Predicts the Disposition and Modulates the Effects of the Cholesterol Absorption Inhibitor Ezetimibe in Humans","volume":"79","author":"Oswald","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1399-0004.2004.00388.x","article-title":"Compound Heterozygosity for Two Non-Synonymous Polymorphisms in NPC1L1 in a Non-Responder to Ezetimibe: NPC1L1 SNPs and Ezetimibe Non-Responsiveness","volume":"67","author":"Wang","year":"2004","journal-title":"Clin. Genet."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1476-511X-4-16","article-title":"NPC1L1 Haplotype Is Associated with Inter-Individual Variation in Plasma Low-Density Lipoprotein Response to Ezetimibe","volume":"4","author":"Hegele","year":"2005","journal-title":"Lipids Health Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ygeno.2005.08.007","article-title":"Sequence Variation in NPC1L1 and Association with Improved LDL-Cholesterol Lowering in Response to Ezetimibe Treatment","volume":"86","author":"Simon","year":"2005","journal-title":"Genomics"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.2174\/1381612824666181010144823","article-title":"Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives","volume":"24","author":"Tsouka","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10557-015-6588-3","article-title":"PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a)","volume":"29","author":"Ferdinand","year":"2015","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6728","DOI":"10.12998\/wjcc.v10.i19.6728","article-title":"Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitor Non Responses in an Adult with a History of Coronary Revascularization: A Case Report","volume":"10","author":"Yang","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1074\/jbc.M116.769430","article-title":"The Proprotein Convertase Subtilisin\/Kexin Type 9-Resistant R410S Low Density Lipoprotein Receptor Mutation: A Novel Mechanism Causing Familial Hypercholesterolemia","volume":"292","author":"Girard","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_81","unstructured":"Goodman, L.S., and Gilman, A. (1955). The Pharmacological Basis of Therapeutics, The Macmillan."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR Control of Metabolism and Cardiovascular Functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.atherosclerosis.2011.08.015","article-title":"Variants in the APOA5 Gene Region and the Response to Combination Therapy with Statins and Fenofibric Acid in a Randomized Clinical Trial of Individuals with Mixed Dyslipidemia","volume":"219","author":"Brautbar","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/sj.ejhg.5202003","article-title":"The Genetic Architecture of Fasting Plasma Triglyceride Response to Fenofibrate Treatment","volume":"16","author":"Smith","year":"2008","journal-title":"Eur. J. Hum. Genet. EJHG"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/00008571-200412000-00005","article-title":"Response to Micronized Fenofibrate Treatment is Associated with the Peroxisome-Proliferator-Activated Receptors \u03b1 G\/C Intron7 Polymorphism in Subjects with Type 2 Diabetes","volume":"14","author":"Foucher","year":"2004","journal-title":"Pharmacogenetics"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.atherosclerosis.2014.03.010","article-title":"Rare LPL Gene Variants Attenuate Triglyceride Reduction and HDL Cholesterol Increase in Response to Fenofibric Acid Therapy in Individuals with Mixed Dyslipidemia","volume":"234","author":"Gao","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/FPC.0000000000000219","article-title":"A Genome-Wide Study of Lipid Response to Fenofibrate in Caucasians: A Combined Analysis of the GOLDN and ACCORD Studies","volume":"26","author":"Irvin","year":"2016","journal-title":"Pharmacogenet. Genom."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/cpt.798","article-title":"Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals with Type 2 Diabetes","volume":"103","author":"Rotroff","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1194\/jlr.P080333","article-title":"An Exome-Wide Sequencing Study of Lipid Response to High-Fat Meal and Fenofibrate in Caucasians from the GOLDN Cohort","volume":"59","author":"Geng","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Aslibekyan, S., Goodarzi, M.O., Frazier-Wood, A.C., Yan, X., Irvin, M.R., Kim, E., Tiwari, H.K., Guo, X., Straka, R.J., and Taylor, K.D. (2012). Variants Identified in a GWAS Meta-Analysis for Blood Lipids Are Associated with the Lipid Response to Fenofibrate. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048663"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2217\/pgs-2019-0140","article-title":"Fibrate Pharmacogenomics: Expanding Past the Genome","volume":"21","author":"House","year":"2020","journal-title":"Pharmacogenomics"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1161\/01.CIR.0000063575.17904.4E","article-title":"American Heart Association\/American College of Cardiology Foundation Guide to Warfarin Therapy","volume":"107","author":"Hirsh","year":"2003","journal-title":"Circulation"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1592\/phco.21.2.235.34106","article-title":"Implications of Cytochrome P450 2C9 Polymorphism on Warfarin Metabolism and Dosing","volume":"21","author":"Redman","year":"2001","journal-title":"Pharmacotherapy"},{"key":"ref_95","first-page":"S119","article-title":"Pharmacogenetics Guided Anticoagulation","volume":"48","author":"Mannhalter","year":"2010","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41569-021-00549-w","article-title":"Pharmacogenetics to Guide Cardiovascular Drug Therapy","volume":"18","author":"Duarte","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clpt.2004.05.005","article-title":"Novel CYP2C9 Genetic Variants in Asian Subjects and Their Influence on Maintenance Warfarin Dose","volume":"76","author":"Zhao","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature02214","article-title":"Mutations in VKORC1 Cause Warfarin Resistance and Multiple Coagulation Factor Deficiency Type 2","volume":"427","author":"Rost","year":"2004","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1182\/blood-2008-09-176222","article-title":"Pharmacogenetic Relevance of CYP4F2 V433M Polymorphism on Acenocoumarol Therapy","volume":"113","author":"Corral","year":"2009","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/cpt.1323","article-title":"Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals","volume":"105","author":"Danese","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.2217\/pgs.12.164","article-title":"Effect of NQO1 and CYP4F2 Genotypes on Warfarin Dose Requirements in Hispanic\u2013Americans and African\u2013Americans","volume":"13","author":"Bress","year":"2012","journal-title":"Pharmacogenomics"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5811\/westjem.2014.12.22933","article-title":"Anticoagulation Drug Therapy: A Review","volume":"16","author":"Harter","year":"2015","journal-title":"West. J. Emerg. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17425255.2016.1194395","article-title":"The Toxicology of Heparin Reversal with Protamine: Past, Present and Future","volume":"12","author":"Sokolowska","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_105","first-page":"4","article-title":"Pharmacogenetic Considerations of Anticoagulant Medication","volume":"96","author":"Miklosz","year":"2018","journal-title":"J. Physiol. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2141.1993.tb03104.x","article-title":"Influence of Demographic Factors on Antithrombin III Activity in a Healthy Population","volume":"84","author":"Tait","year":"1993","journal-title":"Br. J. Haematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/bja\/88.4.467","article-title":"Heparin Resistance","volume":"88","author":"Anderson","year":"2002","journal-title":"Br. J. Anaesth."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2008.000604","article-title":"Functional Consequences of the Prothrombotic SERPINC1 Rs2227589 Polymorphism on Antithrombin Levels","volume":"94","author":"Anton","year":"2009","journal-title":"Haematologica"},{"key":"ref_109","first-page":"1797","article-title":"Progressive Chromogenic Anti-Factor Xa Assay and Its Use in the Classification of Antithrombin Deficiencies","volume":"52","author":"Bereczky","year":"2014","journal-title":"Clin. Chem. Lab. Med. CCLM"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1160\/TH07-01-0067","article-title":"Report of a Novel Kindred with Antithrombin Heparin-Binding Site Variant (47 Arg to His): Demand for an Automated Progressive Antithrombin Assay to Detect Molecular Variants with Low Thrombotic Risk","volume":"98","author":"Rossi","year":"2007","journal-title":"Thromb. Haemost."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/imr.12370","article-title":"The Platelet Fc Receptor, Fc\u03b3RIIa","volume":"268","author":"Qiao","year":"2015","journal-title":"Immunol. Rev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood.V98.5.1634","article-title":"Meta-Analysis of the Association between Low-affinityFc\u03b3 Receptor Gene Polymorphisms and Hematologic and Autoimmune Diseases","volume":"98","author":"Trikalinos","year":"2001","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2016.05.025","article-title":"Pharmacogenetics of Dabigatran Etexilate Interindividual Variability","volume":"144","author":"Dimatteo","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40268-014-0045-9","article-title":"Correlation between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C","volume":"14","author":"Chin","year":"2014","journal-title":"Drugs RD"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jth.13577","article-title":"Interindividual Variability in Dabigatran and Rivaroxaban Exposure: Contribution of ABCB1 Genetic Polymorphisms and Interaction with Clarithromycin","volume":"15","author":"Delavenne","year":"2017","journal-title":"J. Thromb. Haemost. JTH"},{"key":"ref_116","first-page":"494","article-title":"Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect","volume":"7","author":"Daali","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.2174\/1381612824666181018153641","article-title":"Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-Analysis","volume":"24","author":"Xie","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12959-018-0183-3","article-title":"Rivaroxaban Plasma Levels in Patients Admitted for Bleeding Events: Insights from a Prospective Study","volume":"16","author":"Sennesael","year":"2018","journal-title":"Thromb. J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/gtmb.2017.0152","article-title":"CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis","volume":"22","author":"Sychev","year":"2018","journal-title":"Genet. Test. Mol. Biomark."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/nar\/29.1.308","article-title":"dbSNP: The NCBI Database of Genetic Variation","volume":"29","author":"Sherry","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"ref_121","first-page":"825","article-title":"Identification of Variants of CYP3A4 and Characterization of Their Abilities to Metabolize Testosterone and Chlorpyrifos","volume":"299","author":"Dai","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40292-019-00342-4","article-title":"Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery","volume":"26","author":"Sychev","year":"2019","journal-title":"High Blood Press. Cardiovasc. Prev. Off. J. Ital. Soc. Hypertens."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.thromres.2016.07.005","article-title":"ABCB1 SNP Rs4148738 Modulation of Apixaban Interindividual Variability","volume":"145","author":"Dimatteo","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/FPC.0000000000000294","article-title":"Impact of ABCB1, ABCG2, and CYP3A5 Polymorphisms on Plasma Trough Concentrations of Apixaban in Japanese Patients with Atrial Fibrillation","volume":"27","author":"Ueshima","year":"2017","journal-title":"Pharmacogenet. Genom."},{"key":"ref_125","first-page":"43","article-title":"Influence of ABCB1 and CYP3A5 Gene Polymorphisms on Pharmacokinetics of Apixaban in Patients with Atrial Fibrillation and Acute Stroke","volume":"11","author":"Kryukov","year":"2018","journal-title":"Pharm. Pers. Med."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Huppertz, A., Grond-Ginsbach, C., Dumschat, C., Foerster, K.I., Burhenne, J., Weiss, J., Czock, D., Purrucker, J.C., Rizos, T., and Haefeli, W.E. (2019). Unexpected Excessive Apixaban Exposure: Case Report of a Patient with Polymorphisms of Multiple Apixaban Elimination Pathways. BMC Pharmacol. Toxicol., 20.","DOI":"10.1186\/s40360-019-0331-9"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11239-019-01962-2","article-title":"Drug Interactions and Pharmacogenetic Factors Contribute to Variation in Apixaban Concentration in Atrial Fibrillation Patients in Routine Care","volume":"49","author":"Gulilat","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Kanuri, S.H., and Kreutz, R.P. (2019). Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants. J. Pers. Med., 9.","DOI":"10.3390\/jpm9010007"},{"key":"ref_129","first-page":"153","article-title":"An Integrated Pharmacokinetic\/Pharmacogenomic Analysis of ABCB1 and SLCO1B1 Polymorphisms on Edoxaban Exposure","volume":"18","author":"Vandell","year":"2018","journal-title":"Pharm. J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.112.001233","article-title":"Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding","volume":"127","author":"Eriksson","year":"2013","journal-title":"Circulation"},{"key":"ref_131","first-page":"127","article-title":"The Impact of ABCB1 (Rs1045642 and Rs4148738) and CES1 (Rs2244613) Gene Polymorphisms on Dabigatran Equilibrium Peak Concentration in Patients after Total Knee Arthroplasty","volume":"11","author":"Sychev","year":"2018","journal-title":"Pharm. Pers. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bcp.2016.09.003","article-title":"Dabigatran Etexilate Activation Is Affected by the CES1 Genetic Polymorphism G143E (Rs71647871) and Gender","volume":"119","author":"Shi","year":"2016","journal-title":"Biochem. Pharmacol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/11\/2057\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:20:14Z","timestamp":1760131214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/11\/2057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":132,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["genes14112057"],"URL":"https:\/\/doi.org\/10.3390\/genes14112057","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]}}}